Ongoing important trials
BL-B01D1 — post-platinum biliary tract cancer (phase III)
A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy (PANKU-BTC01)
- Phase
- Phase III
- Recruitment
- Recruiting
- Results maturity
- No results
- Publication
- No publication
- Regulatory approval
- No regulatory approval
- NCT
- NCT07582315
- Registry checked
- 2026-10-29
- Editorial update
- 2026-10-29
Not a treatment recommendation. Experimental or ongoing research does not by itself replace standard care.
For patients
What is being studied? After platinum therapy for biliary cancer, a new targeted antibody–drug approach is being studied.
Why promising? Randomizes a BsADC option in post-platinum biliary disease.
What is not proven? No results yet; do not confuse with IDH1/FGFR-targeted therapies.
Is this standard care today? This listing alone does not replace standard care; approval and guideline context require clinician judgment.
For clinicians
Phase III; recruiting. No results yet.
Cancer / population: Biliary tract — Platin bazlı KT sonrası lokal ileri/metastatik biliyer kanser
Intervention: BL-B01D1
Primary endpoint: Protokol tanımlı
Limitations: Yeni faz III; sonuç yok.